Detalhe da pesquisa
1.
Integrative genomic analysis reveals cancer-associated mutations at diagnosis of CML in patients with high-risk disease.
Blood
; 132(9): 948-961, 2018 08 30.
Artigo
em Inglês
| MEDLINE | ID: mdl-29967129
2.
Dynamic modeling of imatinib-treated chronic myeloid leukemia: functional insights and clinical implications.
Nat Med
; 12(10): 1181-4, 2006 Oct.
Artigo
em Inglês
| MEDLINE | ID: mdl-17013383
3.
Comparison of bone marrow high mitotic index metaphase fluorescence in situ hybridization to peripheral blood and bone marrow real time quantitative polymerase chain reaction on the International Scale for detecting residual disease in chronic myeloid leukemia.
Haematologica
; 93(2): 178-85, 2008 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-18223279
4.
Phospho-CRKL monitoring for the assessment of BCR-ABL activity in imatinib-resistant chronic myeloid leukemia or Ph+ acute lymphoblastic leukemia patients treated with nilotinib.
Haematologica
; 93(5): 765-9, 2008 May.
Artigo
em Inglês
| MEDLINE | ID: mdl-18367481
5.
Resistance to targeted therapy in chronic myelogenous leukemia.
Semin Hematol
; 44(1 Suppl 1): S15-24, 2007 Jan.
Artigo
em Inglês
| MEDLINE | ID: mdl-17292737
6.
Enhanced ABL-inhibitor-induced MAPK-activation in T315I-BCR-ABL-expressing cells: a potential mechanism of altered leukemogenicity.
J Cancer Res Clin Oncol
; 138(2): 203-12, 2012 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-22089930